¶ lipoxygenase
¶ Definition
Lipoxygenases (LOX) are a family of non-heme iron-containing dioxygenase enzymes that catalyze the stereospecific insertion of molecular oxygen into polyunsaturated fatty acids (PUFAs), specifically arachidonic acid, EPA, and DHA. The three major isoforms—5-LOX, 12-LOX, and 15-LOX—produce distinct positional isomers of hydroperoxy fatty acids that serve as precursors to both pro-inflammatory mediators (leukotrienes) and specialized pro-resolving mediators (lipoxins, resolvins, protectins, maresins), making LOX pathways the enzymatic crossroads of the eicosanoid class switch.
¶ Picture It
Imagine a Swiss army knife factory that can manufacture both weapons and medical tools from the same raw materials, depending on which blade configuration the workers select. Early in a conflict, the factory runs in "weapons mode"—5-LOX workers grab arachidonic acid off the conveyor belt and forge it into leukotrienes (inflammatory grenades) that recruit troops and amplify the battle. But as the conflict winds down, the same factory floor reconfigures: 15-LOX specialists now take over the same conveyor belt, grabbing the same arachidonic acid but fashioning it into lipoxins—cease-fire signals that actively shut down the inflammatory machinery and begin tissue reconstruction. The factory doesn't change locations or shut down; it simply switches production lines based on cellular context signals. When you add omega-3 fatty acids to the supply chain (EPA and DHA instead of arachidonic acid), the 15-LOX and 12-LOX workshops can now craft even more sophisticated peace-treaty molecules—resolvins, protectins, and maresins—that not only stop the war but actively repair the damage, clear the battlefield debris, and restore diplomatic relations between tissues. The genius is that the same enzymatic machinery produces both war and peace, making LOX pathways the ultimate example of biological context-dependency. Block the whole factory (as NSAIDs do), and you lose both offensive capability AND the ability to negotiate peace—leaving chronic, smoldering conflict.
¶ Mechanism
¶ Core Enzymatic Reaction
All lipoxygenases share a common catalytic mechanism:
- Fe²⁺ → Fe³⁺ activation: The non-heme iron at the active site is oxidized from ferrous (Fe²⁺) to ferric (Fe³⁺) form
- Hydrogen abstraction: LOX removes a hydrogen atom from a 1,4-pentadiene unit in the PUFA substrate (position-specific to each isoform)
- Oxygen insertion: Molecular O₂ is stereospecifically inserted at an adjacent carbon
- Hydroperoxide formation: Produces hydroperoxy-fatty acid intermediates (HPETEs from arachidonic acid, HPEPEs from EPA, HpDHAs from DHA)
¶ 5-LOX Pathway (Pro-inflammatory)
graph TD
AA[Arachidonic Acid] -->|"5-LOX + FLAP"| HPETE[5-HPETE]
HPETE -->|5-LOX| LTA4[Leukotriene A4]
LTA4 -->|LTA4 hydrolase| LTB4["Leukotriene B4<br/>Neutrophil chemoattractant"]
LTA4 -->|LTC4 synthase| LTC4[Leukotriene C4]
LTC4 -->|"γ-glutamyl transpeptidase"| LTD4[Leukotriene D4]
LTD4 -->|dipeptidase| LTE4[Leukotriene E4]
LTB4 --> BLT1[BLT1 receptor activation]
LTC4 --> CysLT[CysLT1/2 receptors]
LTD4 --> CysLT
LTE4 --> CysLT
BLT1 --> Neut["Neutrophil recruitment<br/>Superoxide generation"]
CysLT --> Bron["Bronchoconstriction<br/>Vascular permeability"]
5-LOX specifics:
- Requires FLAP (5-lipoxygenase activating protein) for membrane anchoring and substrate presentation
- Predominantly expressed in: neutrophils, mast cells, macrophages, eosinophils, basophils
- Arachidonic acid → 5-HPETE → LTA₄ (unstable epoxide intermediate)
- LTA₄ bifurcates into:
- LTB₄ (via LTA₄ hydrolase): potent neutrophil chemoattractant, activates BLT1 receptors → NF-κB activation → IL-8, TNF-α production
- Cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄ via LTC₄ synthase): bronchoconstriction (500-1000× more potent than histamine), increased vascular permeability, mucus hypersecretion
¶ 15-LOX Pathway (Pro-resolving from AA)
graph TD
AA[Arachidonic Acid] -->|"15-LOX<br/>Epithelial cells, eosinophils"| HPETE15[15-HPETE]
HPETE15 -->|15-LOX| LXA4[Lipoxin A4]
HPETE15 -->|15-LOX| LXB4[Lipoxin B4]
AA2[Arachidonic Acid] -->|Aspirin-acetylated COX-2| R-15-HETE[15-R-HETE]
R-15-HETE -->|5-LOX in leukocytes| ATL["Aspirin-Triggered Lipoxins<br/>15-epi-LXA4, 15-epi-LXB4"]
LXA4 --> ALX[ALX-FPR2 receptor]
ATL --> ALX
ALX --> Res["↓ Neutrophil recruitment<br/>↓ NF-κB signaling<br/>↑ Efferocytosis<br/>↓ TNF-α, IL-6 production"]
15-LOX specifics:
- Two major subtypes: 15-LOX-1 (ALOX15) and 15-LOX-2 (ALOX15B)
- Expressed in: epithelial cells, eosinophils, macrophages, reticulocytes, airway epithelium
- Arachidonic acid → 15-HPETE → lipoxins (LXA₄, LXB₄)
- Lipoxins act via ALX-FPR2 receptor (also called FPR2/ALX):
Aspirin-triggered pathway:
- Aspirin irreversibly acetylates COX-2 at Ser-530
- Acetylated COX-2 produces 15-R-HETE (instead of prostaglandins) from arachidonic acid
- Neutrophils and leukocytes use 5-LOX to convert 15-R-HETE → aspirin-triggered lipoxins (15-epi-LXA₄, 15-epi-LXB₄)
- ATLs are more potent and metabolically stable than native lipoxins (longer half-life)
¶ 15-LOX/5-LOX Pathway for Omega-3 Resolvins
graph TD
EPA[EPA] -->|"Aspirin-acetylated COX-2<br/>or CYP450"| R-18-HEPE[18-R-HEPE]
R-18-HEPE -->|5-LOX in neutrophils| RvE1[Resolvin E1]
R-18-HEPE -->|5-LOX| RvE2[Resolvin E2]
R-18-HEPE -->|5-LOX| RvE3[Resolvin E3]
DHA[DHA] -->|15-LOX in endothelium| 17-HpDHA[17-HpDHA]
17-HpDHA -->|5-LOX in leukocytes| RvD1[Resolvin D1]
17-HpDHA -->|5-LOX| RvD2[Resolvin D2]
17-HpDHA -->|5-LOX| RvD3[Resolvin D3]
17-HpDHA -->|5-LOX| RvD4[Resolvin D4]
17-HpDHA -->|5-LOX| RvD5[Resolvin D5]
17-HpDHA -->|5-LOX| RvD6[Resolvin D6]
RvE1 --> CMERI[ChemR23, BLT1]
RvD1 --> ALXr[ALX-FPR2, GPR32]
CMERI --> Effect["↓ PMN infiltration<br/>↑ Efferocytosis<br/>↓ Cytokine storm<br/>↑ Tissue regeneration"]
ALXr --> Effect
EPA processing (E-series resolvins):
- EPA → 18-HEPE (via acetylated COX-2 or CYP450 in endothelium)
- Neutrophils use 5-LOX to produce E-series resolvins (RvE1, RvE2, RvE3)
- RvE1 acts via ChemR23 and BLT1 receptors:
DHA processing (D-series resolvins):
- DHA → 17-HpDHA (via 15-LOX in endothelium)
- Leukocytes convert 17-HpDHA via 5-LOX → D-series resolvins (RvD1-D6)
- RvD1 acts via ALX-FPR2 and GPR32:
¶ 12-LOX and Protectin/Maresin Pathways
graph TD
DHA[DHA] -->|15-LOX in leukocytes| 17-HpDHA[17-HpDHA]
17-HpDHA -->|Epoxidation| PD1["Protectin D1<br/>Neuroprotectin D1"]
DHA2[DHA] -->|12-LOX in macrophages| 14-HpDHA[14-HpDHA]
14-HpDHA -->|12-LOX| MaR1[Maresin 1]
14-HpDHA -->|12-LOX| MaR2[Maresin 2]
PD1 --> PD1R["↓ PMN infiltration<br/>↓ TNF-α, IL-1β<br/>↑ T-cell apoptosis<br/>Neuroprotection"]
MaR1 --> MaR1R["↑ Efferocytosis<br/>↑ Tissue regeneration<br/>↓ Neuropathic pain<br/>↑ Wound healing"]
12-LOX specifics:
- Platelet-type 12-LOX (ALOX12) and leukocyte-type 12-LOX (ALOX12B)
- Expressed in: platelets, macrophages, skin, microglia
- DHA → 14-HpDHA → maresins (MaR1, MaR2)
- Maresins promote:
- Macrophage phagocytosis of apoptotic cells and tissue debris
- Tissue regeneration and wound healing
- Reduction of neuropathic pain via TRPV1 modulation
- Resolution of acute lung injury and ARDS
Protectin pathway:
- DHA → 17-HpDHA (via 15-LOX) → epoxidation → Protectin D1 (PD1)
- In neural tissue called neuroprotectin D1 (NPD1)
- PD1/NPD1 actions:
- Reduces infiltration of polymorphonuclear leukocytes
- Promotes T-cell apoptosis (resolves adaptive immune activation)
- Protects neurons from oxidative stress and Aβ toxicity (relevant for Alzheimer's Disease)
- Reduces TNF-α and IL-1β in neuroinflammation
¶ Eicosanoid Class Switch Regulation
The shift from leukotriene to SPM production involves:
- Temporal regulation: Neutrophils arrive early (high 5-LOX for LTB₄), macrophages later (high 15-LOX for lipoxins/resolvins)
- Cell-cell collaboration: Transcellular biosynthesis—epithelial 15-LOX makes intermediate, neutrophil 5-LOX completes lipoxin synthesis
- Substrate availability: Early inflammation → arachidonic acid released → leukotrienes; later → omega-3 fatty acids mobilized from membranes → resolvins
- Redox regulation: Oxidative stress (high H2O2) can inactivate LOX enzymes; antioxidant restoration enables SPM production
- Aspirin effect: COX-2 acetylation redirects arachidonic acid away from prostaglandins toward ATL precursors
¶ Clinical Significance
¶ Central Role in Resolution Pharmacology
LOX pathways represent the enzymatic pivot point where inflammation transitions to resolution—or fails to and becomes chronic. In cPNI practice, understanding LOX isoforms explains why:
- Blocking all eicosanoid synthesis (NSAIDs) prevents both inflammation AND resolution, promoting chronicity
- Supporting substrate availability (omega-3 fatty acids) enables LOX to produce SPMs instead of leukotrienes
- Timing matters: Early 5-LOX activity (leukotrienes) is necessary for pathogen clearance; sustained 5-LOX dominance without 15-LOX class switching creates chronic inflammation
¶ Patient Populations and Conditions
High relevance in:
- Asthma and allergic disease: Cysteinyl leukotrienes (5-LOX products) cause bronchoconstriction; anti-leukotriene drugs (montelukast) block CysLT1 receptors but don't promote resolution
- Chronic pain and fibromyalgia: Failed resolution → sustained leukotriene production → peripheral and central sensitization
- Inflammatory bowel disease: Elevated LTB₄ in intestinal mucosa; EPA/DHA supplementation shifts to RvE1/RvD1 production → mucosal healing
- Cardiovascular disease: 12-LOX in platelets produces pro-thrombotic mediators from arachidonic acid, but anti-thrombotic resolvins from EPA/DHA
- Neuroinflammation and Alzheimer's Disease: NPD1 (from DHA via 15-LOX) protects neurons; DHA deficiency impairs NPD1 synthesis
- Depression: LOX-derived SPMs modulate microglia phenotype; omega-3 deficiency → failed glial resolution → sustained neuroinflammation
¶ Metamodel Integration
Selfish Immune System (Metamodel 1):
- LOX pathways exemplify immune metabolic cost—producing SPMs requires omega-3 substrates and cellular energy (ATP for enzyme function). When resources are diverted to other selfish systems (Selfish Brain, metabolic demands), SPM production fails and inflammation persists.
Evolutionary Mismatch (Metamodel 3):
- Modern omega-6/omega-3 ratio (~16:1) vs. ancestral (~1:1-4:1) means LOX enzymes are substrate-starved for SPM precursors
- Evolutionary expectation: abundant marine/plant omega-3s → robust resolution capacity
- Mismatch reality: seed oil dominance → LOX pathways default to leukotriene production from abundant arachidonic acid
Intermittent Living (Metamodel 5):
- Intermittent inflammatory challenges (acute infections, injuries) were ancestral norm → LOX pathways evolved for acute resolution
- Chronic, unremitting inflammation (obesogenic diet, chronic stress, sedentary lifestyle) → LOX enzymes never complete class switch → failed resolution
¶ Clinical Thresholds and Biomarkers
- Omega-3 Index (EPA+DHA in RBC membranes): Target >8% for optimal SPM synthesis capacity; <4% indicates substrate deficiency for resolvins
- AA/EPA ratio:
:1 ideal for balanced LOX substrate availability; >10:1 indicates pro-inflammatory dominance - LTB₄ levels: Elevated in asthma (>200 pg/mL in sputum), IBD (>500 pg/mL in colonic mucosa)
- RvE1 and RvD1 plasma levels: Measurable in pg/mL range; low levels (<10 pg/mL) correlate with unresolved inflammation in periodontitis, sepsis
- Lipoxin A₄ urine levels: <100 pg/mg creatinine suggests impaired resolution phase in chronic kidney disease
¶ Intervention Strategy
Substrate optimization:
- EPA 2-4 g/day + DHA 1-2 g/day to provide LOX enzymes with resolution-phase substrates
- Increase omega-3 index to >8% over 3-6 months
- Reduce omega-6 intake (seed oils) to rebalance AA/EPA ratio
Natural LOX modulation:
- Ginger (gingerols) and garlic (allicin): inhibit both COX and LOX pathways, reducing prostaglandins AND leukotrienes without blocking SPM synthesis (unlike NSAIDs that only block COX)
- Boswellia (boswellic acids): selective 5-LOX inhibition → reduced leukotrienes while preserving 15-LOX activity for lipoxins
- Curcumin: modulates LOX activity via redox regulation, supports class switching
Low-dose aspirin (75-150 mg/day):
- Acetylates COX-2 → redirects arachidonic acid processing toward ATL precursors
- Enables transcellular biosynthesis of aspirin-triggered resolvins
- Particularly valuable in cardiovascular protection and resolution of low-grade inflammation
Timing considerations:
- Acute phase (0-48 hours): Some leukotriene production necessary for pathogen containment—don't aggressively block 5-LOX early
- Resolution phase (48+ hours): Support 15-LOX substrate availability, ensure omega-3 stores adequate for SPM production
- Chronic inflammation: High-dose omega-3 + aspirin to "force" class switch and break inflammatory chronicity
EXAM FLAG: The concept that the same enzymes make both war and peace molecules is exam-critical. Know that 5-LOX makes leukotrienes (bad) AND contributes to lipoxin/resolvin synthesis (good), so blanket inhibition (montelukast for asthma) may reduce acute symptoms but impair long-term resolution. The cPNI strategy is substrate-shifting (more omega-3) rather than enzyme-blocking.
¶ Key Facts
- 5-LOX requires FLAP (five-lipoxygenase activating protein) for membrane association and substrate delivery—mutation in FLAP reduces leukotriene synthesis
- LTB₄ is 100× more potent as a neutrophil chemoattractant than IL-8; peak levels in acute inflammation = 1-10 nM at tissue sites
- Cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄) are 500-1000× more potent bronchoconstrictors than histamine—cause of aspirin-exacerbated respiratory disease (AERD)
- 15-LOX produces lipoxins from arachidonic acid with EC₅₀ for neutrophil inhibition = 1-10 nM; aspirin-triggered lipoxins are 2-3× more potent
- RvE1 reduces neutrophil infiltration with ED₅₀ = 0.4 ng in peritonitis models; acts via ChemR23 and BLT1 receptors
- RvD1 acts at 0.1-1 nM concentrations via ALX-FPR2 and GPR32 receptors; half-life extended compared to native lipoxins (6-12 hours vs. 30 minutes)
- Maresin 1 stimulates efferocytosis at 10 nM; produced by M2 macrophages via 12-LOX from DHA
- Neuroprotectin D1 (NPD1) protects neurons at 1-10 nM; deficient in Alzheimer's disease brains (40-50% reduction vs. healthy controls)
- Omega-3 Index >8% associated with 30% reduction in cardiovascular mortality and optimal SPM synthesis capacity
- AA/EPA ratio :1 indicates balanced LOX substrate supply; Western diets typically 10-20:1 (pro-inflammatory bias)
- Transcellular biosynthesis: Epithelial cells produce 15-HETE, neutrophils convert it to lipoxins—requires cell-cell contact or exosome transfer
- Aspirin at 75-150 mg/day acetylates >90% of COX-2, redirecting 20-30% of arachidonic acid flux toward ATL precursors
¶ Connections
- arachidonic acid — primary substrate for 5-LOX (leukotrienes) and 15-LOX (lipoxins); substrate abundance determines inflammatory vs. resolution bias
- EPA — omega-3 substrate for 15-LOX and 5-LOX producing E-series resolvins (RvE1-3); competes with arachidonic acid for enzyme active sites
- DHA — omega-3 substrate for 15-LOX (protectins, D-series resolvins) and 12-LOX (maresins); essential for neuroprotection and resolution
- leukotrienes — 5-LOX products from arachidonic acid; LTB₄ is neutrophil chemoattractant, cysteinyl-LTs cause bronchoconstriction and vascular leak
- lipoxins — 15-LOX products from arachidonic acid signaling resolution; act via ALX-FPR2 to inhibit neutrophil chemotaxis and promote efferocytosis
- resolvins — EPA/DHA-derived SPMs produced by 15-LOX and 5-LOX transcellular biosynthesis; RvE1 and RvD1 are most studied for anti-inflammatory potency
- protectins — DHA-derived via 15-LOX; neuroprotectin D1 (NPD1) protects neurons from oxidative stress and reduces amyloid toxicity in Alzheimer's
- maresins — DHA-derived via 12-LOX in macrophages; MaR1 promotes efferocytosis, tissue regeneration, and pain resolution
- eicosanoid class switch — temporal shift from 5-LOX leukotriene production (early inflammation) to 15-LOX lipoxin/resolvin production (resolution phase)
- COX-2 — aspirin acetylation redirects COX-2 to produce 15-R-HETE (ATL precursor) instead of prostaglandins; transcellular partner with 5-LOX
- aspirin-triggered lipoxins — 15-epi-LXA₄ and 15-epi-LXB₄ produced when acetylated COX-2 makes 15-R-HETE, then converted by 5-LOX; more stable than native lipoxins
- ALX-FPR2 receptor — Gαi-coupled receptor for lipoxins and RvD1; activation blocks NF-κB, reduces neutrophil recruitment, stimulates efferocytosis
- neutrophils — express high 5-LOX producing LTB₄ for chemotaxis; also convert intermediates from epithelial 15-LOX into lipoxins (transcellular biosynthesis)
- macrophages — express 15-LOX (M2 phenotype) and 12-LOX producing lipoxins, resolvins, maresins; key resolution effector cells
- omega-3 fatty acids — dietary EPA and DHA provide LOX substrates for SPM synthesis; omega-3 index >8% needed for robust resolution capacity
- NF-κB — transcription factor driving inflammatory gene expression; lipoxins and resolvins block NF-κB nuclear translocation via ALX-FPR2 signaling
- efferocytosis — non-phlogistic clearance of apoptotic neutrophils by macrophages; upregulated by lipoxins, resolvins, maresins acting on phagocyte receptors
- ginger — contains gingerols that inhibit both COX and LOX pathways reducing prostaglandins and leukotrienes without blocking SPM synthesis
- garlic — allicin and sulfur compounds inhibit 5-LOX and 12-LOX reducing leukotriene production; supports vascular health
- inflammation resolution — active process dependent on LOX-derived SPMs; failure of class switching from leukotriene to lipoxin/resolvin synthesis causes chronic inflammation
- asthma — cysteinyl leukotrienes (LTC₄, LTD₄, LTE₄) from 5-LOX cause bronchoconstriction; aspirin-exacerbated respiratory disease involves COX-1 inhibition shunting substrate to 5-LOX
- microglia — brain-resident macrophages expressing 12-LOX and 15-LOX; produce neuroprotectin D1 from DHA for neuroprotection; SPM deficiency linked to neuroinflammation
- Alzheimer's Disease — reduced neuroprotectin D1 levels (40-50% below controls); DHA supplementation may restore NPD1 synthesis and reduce amyloid toxicity
- ARDS — acute respiratory distress syndrome involves excessive 5-LOX leukotriene production; RvD1 and RvE1 reduce alveolar neutrophil infiltration and improve survival in models
- IBD — inflammatory bowel disease shows elevated LTB₄ in intestinal mucosa; EPA/DHA supplementation increases mucosal RvE1 levels and promotes healing
¶ Module References
- Module 5